Bilateral Iridociliary T-Cell Lymphoma

Total Page:16

File Type:pdf, Size:1020Kb

Bilateral Iridociliary T-Cell Lymphoma CLINICOPATHOLOGIC REPORTS, CASE REPORTS, AND SMALL CASE SERIES SECTION EDITOR: W. RICHARD GREEN, MD lomata acuminata. While receiving flamed fibrovascular cores Conjunctival Papillomas highly active antiretroviral therapy (Figure 2). Nucleated keratino- Caused by Human (HAART), including indinavir sul- cytes from the paraffin-embedded Papillomavirus Type 33 fate, nevirapine, and combivir, he has specimen were microdissected un- had no new opportunistic infections der direct visualization. After protein- Conjunctival papillomas are associ- and his CD4+ cell count has in- ase K digestion, DNA sequences for ated with human papillomavirus creased above 200/mm3. He sought HPV genotypes 16, 18, and 33 were (HPV) infection. In children, the le- ophthalmic care because of occa- amplified with a kit (PCR Human sions are typically manifestations of sional bleeding from the conjuncti- Papillomavirus Detection Kit; Pan an infection acquired during deliv- val lesions. An initial ocular exami- Vera, Madison, Wis) and transblot- ery.1 In adults, conjunctival papillo- nation revealed bilateral inferior ted for Southern blot hybridization. mas are most likely venereal and are palpebral conjunctival papillomas that Briefly, the common sense primer for often associated with anogenital le- were excised from the right eye. The HPV types 16, 18, and 33 was 5Ј- sions.2 Papillomas due to HPV more results of a histopathologic examina- AAGGGCGTAACCGAAATC- frequently progress to malignancy in tion showed conjunctival papillo- GGT-3Ј and the antisense primers of patients with the human immuno- mas without atypia. The results of an each HPV strain were as follows: 5Ј- deficiency virus (HIV) infection.3 Hu- immunohistochemistry test for HPV GTTTGCAGCTCTGTGCATA-3Ј for man papillomavirus types 6, 11, 16, types 6, 11, 16, 18, 31, and 33 was HPV 16, 5Ј-GTGTTCAGTTCCGT- and 18 have been identified in be- negative. The conjunctival lesions re- GCACA-3Ј for HPV 18, and 5Ј- nign and malignant conjunctival le- curred, and he was referred to the Na- GTCTCCAATGCTTGGCACA-3Ј for sions using various antigen and DNA tional Eye Institute, Bethesda, Md. HPV 33. The hybridization probes detection techniques.2 For the first The results of our examination were were 5Ј-CATTTTATGCAC- time, to our knowledge, we report the unremarkable, except for the pres- CAAAAGAGAACTGCAATG-3Ј for finding of HPV type 33 in conjunc- ence of 1.2- to 1.5-mm nodular le- HPV 16, 5Ј-TGAGAAACACACCA- tival papillomas excised from an HIV- sions on the right upper and lower CAATACTATGGCGCGC-3Ј for positive patient. palpebral conjunctiva and large, con- HPV 18, and 5Ј-CATTTTGCAG- fluent, verrucous lesions involving the TAAGGTACTGCACGACTATG-3Ј Report of a Case. A 34-year-old HIV- left upper and lower palpebral con- for HPV 33. The polymerase chain re- positive man complained of bilateral junctiva (Figure 1). A left palpe- action was performed for each HPV conjunctival lesions of 4 years’ dura- bral conjunctival excisional biopsy strain under the following condi- tion. Ten years earlier, he was diag- was performed. A histopathologic ex- tions: 94° for 30 seconds to denature nosed as having HIV after develop- amination of the biopsy specimen re- the primers, 55° for 2 minutes for ing pneumocystis pneumonia, a vealed papillary fronds of acanthotic primer annealing, and 72° for 2 min- Mycobacterium avium-intracellulare squamous epithelium without atypia utes for primer extension. The reac- infection, and perianal HPV condy- and koilocytic changes overlying in- tion was repeated for 35 cycles, con- Figure 1. Diffuse left lower palpebral conjunctival papillomas. Figure 2. Photomicrograph showing multiple papillary fronds of acanthotic conjunctival epithelium without atypia or koilocytic changes overlying fibrovascular cores infiltrated by subacute inflammatory cells (arrow) (hematoxylin-eosin, original magnification ϫ400). (REPRINTED) ARCH OPHTHALMOL / VOL 120, FEB 2002 WWW.ARCHOPHTHALMOL.COM 202 ©2002 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/26/2021 cluding with a final extension at 72° for 10 minutes. The results demon- strated HPV type 33 DNA sequences in the epithelium of the conjunctival Case papillomas (Figure 3). Postopera- tively, the patient was unavailable for follow-up. Comment. Human papillomavirus is Positive an oncogenic double-stranded DNA Control papovavirus that infects keratino- cytes and causes benign and malig- nant hyperproliferative squamous 12 3 epithelial tumors. With approxi- mately 100 subtypes identified, HPV Figure 3. Southern blot detection of amplified DNA polymerase chain reaction products for human is now the most common sexually papillomavirus (HPV) types 16, 18, and 33 from the epithelia microdissected from the conjunctival papillomas. Lane 1 indicates HPV type 16; lane 2, HPV type 18; and lane 3, HPV type 33. transmitted disease. Human papillo- mavirus is the cause of verrucae (skin warts), condylomata acuminata (ve- cently HPV type 33 has been asso- fections on the risk of ocular neo- nereal or genital warts), and muco- ciated with breast cancer in Chi- plasia. We report for the first time, cutaneous papillomas, which repre- nese and Japanese patients.9 to our knowledge, the presence of sent 7% to 12% of all conjunctival Infection with HIV increases the HPV type 33 in conjunctival papil- lesions.1,4 Most commonly associ- risk for HPV-associated malignancy lomas. Although the conjunctival ated with benign anogenital lesions and may be a cofactor linking HPV papillomas in our patient were be- and respiratory papillomas, HPV infection and neoplasia.5 The immu- nign, we suspect that the coinci- types 6 and 11 are classified as low- nodeficiency secondary to HIV may dence of the HIV infection and the risk subtypes because they rarely facilitate the oncogenic effects of oncogenic HPV type 33 places the progress to invasive cancer. Human HPV by altering the host susceptibil- patient at an increased risk for re- papillomavirus types 16 and 18 are ity to HPV infection and impairing current and persistent conjunctival considered high risk because they are immune tumor surveillance. A di- papillomas and a conjunctival ma- associated with epithelial dysplasia rect molecular interaction between lignancy. Further follow-up is and squamous cell carcinomas, par- HIV and HPV could also promote needed to determine if HAART will ticularly in the uterine cervix and anal the development of cancer. Re- ameliorate or potentiate the pa- canal. Human papillomavirus types cently, it has been shown that the tient’s risk of ocular disease. 31, 33, 35, 45, 51, 52, and 56 have HIV-1 tat protein potentiates the ex- an intermediate risk of malig- pression of HPV oncoproteins.5 Ronald R. Buggage, MD nancy.5 The effect of HAART in HIV- Janine A. Smith, MD Conjunctival HPV infection infected patients with HPV disease Defen Shen, PhD may be established during delivery is unclear. Heard and coworkers10 at- Chi-Chao Chan, MD through an infected birth canal, by tributed the reduced prevalence of Bethesda, Md sexual contact, or by autoinocula- cervical HPV lesions in HIV- tion. Human papillomavirus anti- positive women treated with HAART + Corresponding author and reprints: Dr gens are reported in 5% to 45% of to their increased CD4 cell count. Buggage, National Eye Institute, Na- conjunctival papillomas, with HPV Similarly, anal HPV lesions were tional Institutes of Health, 10 Center Dr, types 6 and 11 most commonly more likely to regress in HIV- + Bldg 10, Room 10N112, Bethesda, MD found in papillomas from children positive men with higher CD4 cell 20892-1857 (e-mail: BuggageR@intra and HPV types 16 and 18 more fre- counts who were receiving HAART. .nei.nih.gov). quently associated with dysplasia Other studies5 involving HIV- and carcinoma in older patients. positive men with anal HPV lesions 1. McDonnell PJ, McDonnell JM, Kessis T, et al. Detection of human papillomavirus type 6/11 Normal conjunctiva has also been who were receiving HAART, how- DNA in conjunctival papillomas by in situ hy- 2,6 shown to harbor HPV antigens. ever, suggest that anal HPV does not bridization with radioactive probes. Hum Pathol. Human papillomavirus type 33 regress and that the improved sur- 1987;18:1115-1119. 2. Miller DM, Brodell RT, Levine MR. The conjunc- is an uncommon genotype found in vival from HAART may paradoxi- tival wart: report of a case and review of treat- benign, dysplastic, and malignant le- cally cause an increased risk of anal mentoptions.OphthalmicSurg.1994;25:545-548. sions. In a study7 defining the dis- cancer. 3. Waddell KM, Lewallen S, Lucas SB, et al. Car- cinoma of the conjunctiva and HIV infection tribution of HPV genotypes in male An increased incidence of con- in Uganda and Malawi. Br J Ophthalmol. 1996; genital lesions, it was detected in junctival malignancy in Africa has 80:503-508. 4. Cotran RS, Kumar N, Collins T. Neoplasia: Rob- only 1 (0.6%) of 175 specimens. Se- been attributed to the combination bins Pathologic Basis of Disease. Philadelphia, Pa: ropositivity to HPV type 33 in- of HIV-induced immunosuppres- WB Saunders Co; 1999:311-312, 1048-1051. creased with age in a study8 of east- sion, HPV infection, and UV light ex- 5. Palefsyk JM. Anal squamous intraepithelial le- 3 sions in human immunodeficiency virus– ern European women. Primarily posure. This finding supports the positive men and women. Semin Oncol. 2000; found in anogenital lesions, re- combined effect of HIV and HPV in- 27:471-479. (REPRINTED) ARCH OPHTHALMOL / VOL 120, FEB 2002 WWW.ARCHOPHTHALMOL.COM 203 ©2002 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/26/2021 6. Naghasfar Z, McDonnell PJ, McDonnell JM, et al. Genital tract papillomavirus type 6 in re- current conjunctival papilloma. Arch Ophthal- mol. 1986;104:1814-1815. 7. Grce M, Husnjak K, Skerlev M, Lipozencic J, Pavelic K. Detection and typing of human pap- illomaviruses by means of polymerase chain re- action and fragment length polymorphism in male genital lesions.
Recommended publications
  • Glaucoma Related to Ocular and Orbital Tumors Sonal P
    Chapter Glaucoma Related to Ocular and Orbital Tumors Sonal P. Yadav Abstract Secondary glaucoma due to ocular and orbital tumors can be a diagnostic challenge. It is an essential differential to consider in eyes with a known tumor as well as with unilateral, atypical, asymmetrical, or refractory glaucoma. Various intraocular neoplasms including iris and ciliary body tumors (melanoma, metasta- sis, lymphoma), choroidal tumors (melanoma, metastasis), vitreo-retinal tumors (retinoblastoma, medulloepithelioma, vitreoretinal lymphoma) and orbital tumors (extra-scleral extension of choroidal melanoma or retinoblastoma, primary orbital tumors) etc. can lead to raised intraocular pressure. The mechanisms for glaucoma include direct (tumor invasion or infiltration related outflow obstruction, tra- becular meshwork seeding) or indirect (angle closure from neovascularization or anterior displacement or compression of iris) or elevated episcleral venous pressure secondary to orbital tumors. These forms of glaucoma need unique diagnostic techniques and customized treatment considerations as they often pose therapeutic dilemmas. This chapter will review and discuss the mechanisms, clinical presenta- tions and management of glaucoma related to ocular and orbital tumors. Keywords: ocular tumors, secondary glaucoma, orbital tumors, angle infiltration, neovascular glaucoma, neoplastic glaucoma 1. Introduction With the advent of constantly evolving and advancing ophthalmic imaging tech- niques as well as surgical modalities in the field of ophthalmic diseases, diagnostic accuracy, and treatment outcomes of ocular as well as orbital tumors have improved remarkably over the past few years. Raised intraocular pressure (IOP) is known to be one of the presenting features or associated finding for numerous ocular as well as orbital tumors. Ocular and orbital tumors can cause secondary glaucoma due to various mechanisms.
    [Show full text]
  • ICO Residency Curriculum 2Nd Edition and Updated Community Eye Health Section
    ICO Residency Curriculum 2nd Edition and Updated Community Eye Health Section The International Council of Ophthalmology (ICO) Residency Curriculum offers an international consensus on what residents in ophthalmology should be taught. While the ICO curriculum provides a standardized content outline for ophthalmic training, it has been designed to be revised and modified, with the precise local detail for implementation left to the region’s educators. Download the Curriculum from the ICO website: icoph.org/curricula.html. www.icoph.org Copyright © International Council of Ophthalmology 2016. Adapt and translate this document for your noncommercial needs, but please include ICO credit. All rights reserved. First edition 201 6 . First edition 2006, second edition 2012, Community Eye Health Section updated 2016. International Council of Ophthalmology Residency Curriculum Introduction “Teaching the Teachers” The International Council of Ophthalmology (ICO) is committed to leading efforts to improve ophthalmic education to meet the growing need for eye care worldwide. To enhance educational programs and ensure best practices are available, the ICO focuses on "Teaching the Teachers," and offers curricula, conferences, courses, and resources to those involved in ophthalmic education. By providing ophthalmic educators with the tools to become better teachers, we will have better-trained ophthalmologists and professionals throughout the world, with the ultimate result being better patient care. Launched in 2012, the ICO’s Center for Ophthalmic Educators, educators.icoph.org, offers a broad array of educational tools, resources, and guidelines for teachers of residents, medical students, subspecialty fellows, practicing ophthalmologists, and allied eye care personnel. The Center enables resources to be sorted by intended audience and guides ophthalmology teachers in the construction of web-based courses, development and use of assessment tools, and applying evidence-based strategies for enhancing adult learning.
    [Show full text]
  • Download Report Appendixes [PDF · 224
    Appendices Appendix A. Selected Internet Links Appendix Table A1. Internet links for radiotherapy organizations Organization URL address Deutsche Gesellschaft fur http://www.degro.org/jsp_public/cms/index.jsp Radiooncologie European Society for Therapeutic http://www.estroweb.org/estro/index.cfm Radiology and Oncology American Society for Therapeutic http://www.astro.org/ Radiology and Oncology National Association for Proton http://www.proton-therapy.org/ Therapy Particle Therapy Cooperative http://ptcog.web.psi.ch/ Group (Accessed June 16, 2008) Appendix Table A2. Internet links for particle beam instrumentation companies Company URL address Ion Beam Applications (IBA) http://www.iba-worldwide.com/ Solutions Still River Systems Inc http://www.stillriversystems.com/ Optivus Proton Therapy http://www.optivus.com/ Siemens http://www.medical.siemens.com/ Hitachi: Proton beam Therapy http://www.pi.hitachi.co.jp/rd-eng/product/industrial-sys/accelerator- sys/proton-therapy-sys/proton-beam-therapy/index.html ACCEL Instruments http://www.proton-therapy.com/ (Accessed June 16, 2008) Appendix Table A3. Internet links for particle beam treatment centers in the USA Center/Institute URL address Francis H. Burr Proton Therapy http://www.massgeneral.org/cancer/about/providers/radiation/proton/i Center (NPTC) ndex.asp Loma Linda University Proton http://www.llu.edu/proton/index.html Therapy Center University of California, Crocker http://media.cnl.ucdavis.edu/crocker/website/default.php Nuclear Lab Midwest Proton Radiotherapy http://www.mpri.org/ Institute, Bloomington M.D. Anderson Proton Therapy http://www.mdanderson.org/care_centers/radiationonco/ptc/ Center, Houston University of Florida Proton http://www.floridaproton.org/ Therapy Institute, Jacksonville (Accessed June 16, 2008) A-1 Appendix B.
    [Show full text]
  • Ocular Oncology and Pathology 2018 Hot Topics in Ocular Pathology and Oncology— an Update
    Ocular Oncology and Pathology 2018 Hot Topics in Ocular Pathology and Oncology— An Update Program Directors Patricia Chévez-Barrios MD and Dan S Gombos MD In conjunction with the American Association of Ophthalmic Oncologists and Pathologists McCormick Place Chicago, Illinois Saturday, Oct. 27, 2018 Presented by: The American Academy of Ophthalmology 2018 Ocular Oncology and Pathology Subspecialty Day Advisory Committee Staff Planning Group Daniel S Durrie MD Melanie R Rafaty CMP DES, Director, Patricia Chévez-Barrios MD Associate Secretary Scientific Meetings Program Director Julia A Haller MD Ann L’Estrange, Subspecialty Day Manager Dan S Gombos MD Michael S Lee MD Carolyn Little, Presenter Coordinator Program Director Francis S Mah MD Debra Rosencrance CMP CAE, Vice R Michael Siatkowski MD President, Meetings & Exhibits Former Program Directors Kuldev Singh MD MPH Patricia Heinicke Jr, Copy Editor 2016 Carol L Shields MD Mark Ong, Designer Maria M Aaron MD Gina Comaduran, Cover Designer Patricia Chévez-Barrios MD Secretary for Annual Meeting 2014 Hans E Grossniklaus MD Arun D Singh MD ©2018 American Academy of Ophthalmology. All rights reserved. No portion may be reproduced without express written consent of the American Academy of Ophthalmology. ii Planning Group 2018 Subspecialty Day | Ocular Oncology & Pathology 2018 Ocular Oncology and Pathology Planning Group On behalf of the American Academy of Ophthalmology and the American Association of Ophthalmic Oncologists and Pathologists, it is our pleasure to welcome you to Chicago and
    [Show full text]
  • Luth): a 15 Year Review
    REVIEW OF MANAGEMENT OF ORBITO-OCULAR MALIGNANCIES IN LAGOS UNIVERSITY TEACHING HOSPITAL (LUTH): A 15 YEAR REVIEW BY DR. ADEWUMI OLABIMPE ALABI (MBBS, IBADAN) AF/012/11/002/554 A PART II DISSERTATION SUBMITTED IN PARTIAL FULFILMENT OF THE AWARD OF FELLOWSHIP IN RADIOTHERAPY, FACULTY OF RADIOLOGY, NATIONAL POSTGRADUATE MEDICAL COLLEGE OF NIGERIA. NOVEMBER, 2015 1 DECLARATION I declare that this study titled “REVIEW OF MANAGEMENT OF ORBITO- OCULAR MALIGNANCIES IN LAGOS UNIVERSITY TEACHING HOSPITAL (LUTH): A 15 YEAR REVIEW” was carried out by me and to the best of my knowledge contains no material previously published or written by another person, nor material which has been submitted or accepted for the award of any degree or Fellowship except where due acknowledgement has been made in the text. _______________________________ DR. ADEWUMI OLABIMPE ALABI (MBBS, IBADAN) 2 CERTIFICATION This is to certify that this research project “REVIEW OF MANAGEMENT OF ORBITO- OCULAR MALIGNANCIES IN LAGOS UNIVERSITY TEACHING HOSPITAL (LUTH) : A 15 YEAR REVIEW” was conducted in the Departments of Radiotherapy and Ophthalmology (Guinness Eye Centre), LUTH, Idi-araba, Lagos and Supervised by: Professor A. T. Ajekigbe Head, Department of Radiotherapy/Consultant Clinical & Radiation oncologist, Lagos University Teaching Hospital, Idi-araba, Lagos. Signature/Date: _____________________ Professor (Mrs) F. B. Akinsola Head, 3 Department of Ophthalmology/Consultant Ophthalmologist, Guinness Eye Centre, Lagos University Teaching Hospital, Idi-araba, Lagos. Signature/Date: _____________________ Department of Radiotherapy, Lagos University Teaching Hospital, Idi – araba, Lagos state. 2nd of August, 2015. This is to certify that this research project “REVIEW OF MANAGEMENT OF ORBITO- OCULAR MALIGNANCIES IN LAGOS UNIVERSITY TEACHING HOSPITAL (LUTH) : A 15 YEAR REVIEW” by Dr Alabi, Adewumi Olabimpe of the Department Of Radiotherapy, LUTH was conducted in the Departments of Radiotherapy and Ophthalmology (Guinness Eye Centre), LUTH, Idi-araba, Lagos State.
    [Show full text]
  • Differential Diagnoses Symptoms and Other Useful Lists and Tables Signs for Ophthalmologists Case Presentations
    Differential Diagnoses Symptoms and other Useful Lists and Tables Signs For Ophthalmologists Case Presentations Kenn Freedman MD PhD Department of Ophthalmology and Visual Sciences Texas Tech University Health Sciences Center Lubbock, Texas USA Acknowledgments and Disclaimer The differential diagnoses and lists contained herein are not meant to be exhaustive, but are to give in most cases the most common causes of many ocular / visual symptoms, signs and situations. Included also in these lists are also some less common, but serious conditions that must be “ruled-out”. These lists have been based on years of experience, and I am grateful for God’s help in developing them. I also owe gratitude to several sources* including Roy’s classic text on Ocular Differential Diagnosis. * Please see references at end of document This presentation, of course, will continue to be a work in progress and any concerns or suggestions as to errors or omissions or picture copyrights will be considered. Please feel free to contact me at [email protected] Kenn Freedman Lubbock, Texas - October 2018 Disclaimer: The diagnostic algorithm for the diagnosis and management of Ocular or Neurological Conditions contained in this presentation is not intended to replace the independent medical or professional judgment of the physician or other health care providers in the context of individual clinical circumstances to determine a patient’s care. Use of this Presentation The lists are divided into three main areas 1. Symptoms 2. Signs from the Eight Point Eye Exam 3. Common Situations and Case Presentations The index for all of the lists is given on the following 3 pages.
    [Show full text]
  • Uveal Melanoma National Guidelines
    Uveal Melanoma Guidelines – Draft for Consultation Uveal Melanoma National Guidelines Draft for public consulation June 2014 This project is the independent work of the Uveal Melanoma Guideline Development Group and is funded by Melanoma Focus (http://melanomafocus.com/) um_guideline_cons_draft_v2_23_6_14 Last saved by Nancy Turnbull Date 16 June 2014 Page 1 of 93 Uveal Melanoma Guidelines – Draft for Consultation Uveal Melanoma 1. Executive Summary ......................................................................................................................... 6 1.1 Care Pathway .......................................................................................................................... 6 1.2 Recommendations .................................................................................................................. 8 1.2.1 Patient Choice and Shared decision-making .................................................................. 8 1.2.2 Service Configuration ...................................................................................................... 8 1.2.3 General Guidance............................................................................................................ 8 1.2.4 Primary management ..................................................................................................... 9 1.2.5 Prognostication ............................................................................................................. 11 1.2.6 Surveillance ..................................................................................................................
    [Show full text]
  • Uveal Melanoma National Guidelines
    Uveal Melanoma Guidelines January 2015 Uveal Melanoma National Guidelines January 2015 Authors: Nathan P, Cohen V, Coupland S, Curtis K, Damato B, Evans J, Fenwick S, Kirkpatrick L, Li O, Marshall E, McGuirk K, Ottensmeier C, Pearce N, Salvi S, Stedman B, Szlosarek P, Turnbull N This project is the independent work of the Uveal Melanoma Guideline Development Group and is funded by Melanoma Focus (http://melanomafocus.com/) Page 1 of 112 Uveal Melanoma Guidelines January 2015 Uveal Melanoma 1. Executive Summary ......................................................................................................................... 6 1.1 Care Pathway .......................................................................................................................... 6 1.2 Recommendations ................................................................................................................ 10 1.2.1 Patient Choice and Shared decision-making ................................................................ 10 1.2.2 Service Configuration .................................................................................................... 10 1.2.3 General Guidance.......................................................................................................... 10 1.2.4 Primary management ................................................................................................... 11 1.2.5 Prognostication ............................................................................................................. 14
    [Show full text]
  • Ciliary Body Melanoma
    Central JSM Ophthalmology Case Report *Corresponding author Maria Luisa Gois da Fonseca, Department of Retina and Vitreous, Federal Fluminense University Niterói, Marques do Parana Avenue 303 Centro- Niterói, Brazil, Ciliary Body Melanoma: A Case Tel: 24033900 21 26299000; Email: [email protected] Submitted: 20 April 2020 Report With A Satisfactory Accepted: 29 April 2020 Published: 30 April 2020 Clinical Evolution ISSN: 2333-6447 Copyright Carolina Correa Leal Lima, Maria Luisa Gois da Fonseca*, © 2020 Leal Lima CC, et al. Guilherme Herzog Neto and Raul Nunes Galvarro Vianna OPEN ACCESS Department of Retina and Vitreous, Federal Fluminense University Niterói, Brazil Keywords Abstract • Melanoma • Oculoplastics Ciliary body melanomas are rare uveal disorders. Due to its anatomical location, it • Oncology is usually incidentally discovered in advanced stages. There is no established treatment • Ophthalmology for metastatic disease and the one-year survival rate of these patients is only fifteen • Uveal melanoma percent. We intend to report a case of ciliary body melanoma with good clinical outcomes. INTRODUCTION Ciliary body melanomas represent twelve percent of the uveal melanomas. Usually asymptomatic, it is incidentally discovered in the sixth decade of life. Owing to the anatomy of the eye, commonly the diagnosis is only made in advanced stages [1]. The present article intends to report a ciliary body melanoma case and literature review. CASE PRESENTATION Male, 80 years, one-eyed, right eye vision loss after a central retinal vein occlusion that evolved to neovascular glaucoma, has been attended at Federal Fluminense University Hospital Antonio Pedro for left eye (LE), cataracts surgery evaluation. At the Figure 1 Biomicroscopy illustrating vascularized hyperpigmented examination, best-corrected visual acuity (BCVA), was no light nodular lesion between bulbar conjunctiva and inferior tarsus in the perception right eye (RE), and 20/50 LE.
    [Show full text]
  • Primary Cysts of the Iris
    PRIMARY CYSTS OF THE IRIS BY Jerry A. Shields, MD INTRODUCTION PRIMARY IRIS CYSTS ARE RELATIVELY UNCOMMON, AND THERE HAVE BEEN NO LARGE studies which define the clinical characteristics and natural course of these lesions. The purpose of this thesis is to summarize the available literature on primary iris cysts, to review the clinical data on 62 affected patients who have been evaluated and followed by the author, and to document their clinical features with anterior segment photographs. On the basis of these observations, certain misconceptions in the literature regarding primary iris cysts will be challenged and a simple classification of such lesions will be proposed. DEFINITIONS For purposes of this report a cyst is defined as an epithelial-lined space. A primary iris cyst is an epithelial-lined space which involves a portion of the iris and which has no recognizable etiology. A secondary iris cyst is an epithelial-lined space which involves a portion of the iris and which has a recognizable etiology, such as surgical trauma, nonsurgical trauma, or miotic drugs. Such secondary iris cysts have already been thoroughly and accurately described in the literature. They will be included in the overall classification but will not be included in the statistical part of this report. REVIEW OF THE LITERATURE The literature on primary iris cysts is rather confusing because most reports have cited only a single example or a small series of patients and no writer has accumulated enough cases to classify the lesions into clini- cally meaningful categories. A review of the available literature indicated that such cysts may occur on the pupillary margin, in the posterior epithelial layer of the iris, or as free-floating cysts in the aqueous or vitreous chambers.
    [Show full text]
  • Pigmented Medulloepithelioma of the Ciliary Body
    CLINICOPATHOLOGIC REPORTS, CASE REPORTS, AND SMALL CASE SERIES SECTION EDITOR: W. RICHARD GREEN, MD lomata acuminata. While receiving flamed fibrovascular cores Conjunctival Papillomas highly active antiretroviral therapy (Figure 2). Nucleated keratino- Caused by Human (HAART), including indinavir sul- cytes from the paraffin-embedded Papillomavirus Type 33 fate, nevirapine, and combivir, he has specimen were microdissected un- had no new opportunistic infections der direct visualization. After protein- Conjunctival papillomas are associ- and his CD4+ cell count has in- ase K digestion, DNA sequences for ated with human papillomavirus creased above 200/mm3. He sought HPV genotypes 16, 18, and 33 were (HPV) infection. In children, the le- ophthalmic care because of occa- amplified with a kit (PCR Human sions are typically manifestations of sional bleeding from the conjuncti- Papillomavirus Detection Kit; Pan an infection acquired during deliv- val lesions. An initial ocular exami- Vera, Madison, Wis) and transblot- ery.1 In adults, conjunctival papillo- nation revealed bilateral inferior ted for Southern blot hybridization. mas are most likely venereal and are palpebral conjunctival papillomas that Briefly, the common sense primer for often associated with anogenital le- were excised from the right eye. The HPV types 16, 18, and 33 was 5Ј- sions.2 Papillomas due to HPV more results of a histopathologic examina- AAGGGCGTAACCGAAATC- frequently progress to malignancy in tion showed conjunctival papillo- GGT-3Ј and the antisense primers of patients with the human immuno- mas without atypia. The results of an each HPV strain were as follows: 5Ј- deficiency virus (HIV) infection.3 Hu- immunohistochemistry test for HPV GTTTGCAGCTCTGTGCATA-3Ј for man papillomavirus types 6, 11, 16, types 6, 11, 16, 18, 31, and 33 was HPV 16, 5Ј-GTGTTCAGTTCCGT- and 18 have been identified in be- negative.
    [Show full text]
  • Brachytherapy for Patients with Uveal Melanoma: Historical Perspectives and Future Treatment Directions
    Journal name: Clinical Ophthalmology Article Designation: Review Year: 2018 Volume: 12 Clinical Ophthalmology Dovepress Running head verso: Brewington et al Running head recto: UM brachytherapy-early beginning to the molecular era open access to scientific and medical research DOI: 129645 Open Access Full Text Article REVIEW Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions Beatrice Y Brewington1 Abstract: Surgical management with enucleation was the primary treatment for uveal melanoma Yusra F Shao2 (UM) for over 100 years. The Collaborative Ocular Melanoma Study confirmed in 2001 that Fredrick H Davidorf1 globe-preserving episcleral brachytherapy for UM was safe and effective, demonstrating Colleen M Cebulla1 no survival difference with enucleation. Today, brachytherapy is the most common form of radiotherapy for UM. We review the history of brachytherapy in the treatment of UM and the 1Havener Eye Institute, Department of Ophthalmology and Visual Science, evolution of the procedure to incorporate fine-needle-aspiration biopsy techniques with DNA- Ohio State University, 2Medical and RNA-based genetic prognostic testing. Student Research Program, The Ohio Keywords: brachytherapy, uveal melanoma, UM, fine-needle-aspiration biopsy, genetic State University College of Medicine, Columbus, OH, USA prognostic testing, molecular markers Introduction In the early 1900s, patients often presented with large, symptomatic uveal melanoma (UM), for which the primary course of treatment was enucleation.
    [Show full text]